The US Food & Drug Administration’s Arthritis Advisory Committee has made a unanimous decision in favor of licensing Amgen’s biosimilar version of AbbVie’s adalimumab (Humira), ABP 501.
The blockbuster biologic Humira is approved for the treatment of several autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis.
While pricing data aren’t yet available, putting patients on far less costly biosimilars such as Amgen’s offering is expected to to save healthcare providers billions of dollars annually.